Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8273a in advanced solid tumors or lymphomas
NCT02076451Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of DS-8273a in solid tumor and lymphoma (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of adverse events at 21 days and Maximum Tolerated Dose at 21 days. Started Feb 2014; status: completed.
02
Drugs
DS-8273a
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02076451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076451.